Cancer News and Research

Latest Cancer News and Research

Routine use of pelvic CT scans in Wilms tumor questioned

Omitting pelvic computed tomography scans from the routine surveillance of off-therapy patients with Wilms tumor could reduce radiation exposure without compromising relapse detection rates, researchers report.

2 Jul 2012

Procoagulant–fibrinolytic balance may predict hepatectomy thrombosis

An imbalance in procoagulant/fibrinolytic blood factors may point to an increased risk for thrombosis following liver surgery, research suggests.

2 Jul 2012

Vitamin D–calcium combo reduces mortality in elderly

The results of a meta-analysis of individual patient data show that vitamin D supplementation with calcium reduces mortality rates in the elderly.

2 Jul 2012

Study investigates association between SCC and cutaneous HPV types belonging to five different genera

Researchers at Moffitt Cancer Center and colleagues at the University of South Florida, the German Cancer Research Center in Heidelberg, and the International Agency for Research on Cancer in Lyon, France, conducted a case control study and found associations between having antibodies to certain types of cutaneous human papillomavirus (HPV) and a kind of skin cancer called squamous cell carcinoma (SCC).

2 Jul 2012

Prostate Cancer Center of New Jersey earns ACR-ASTRO accreditation in radiation oncology

The Prostate Cancer Center of New Jersey, a partnership between AKSM/Oncology and the Urology Group of New Jersey (UGNJ), is the latest in a rapidly growing list of prostate-only treatment centers to earn the high honor of a three-year term of accreditation in radiation oncology.

2 Jul 2012

Onyx commences ENDEAVOR Kyprolis Phase 3 trial for relapsed multiple myeloma

Onyx Pharmaceuticals, Inc. announced today that the company has begun enrollment in the ENDEAVOR trial, a Phase 3 trial evaluating Kyprolis in combination with dexamethasone, versus bortezomib with dexamethasone in patients with relapsed multiple myeloma.

2 Jul 2012

Current diagnosis and treatment approaches for rheumatoid arthritis

In the realm of deadly and disabling diseases, conditions such as cancer and Alzheimer's seem to attract the most media attention. But there are others that take a similarly high toll, and rheumatoid arthritis is one of them, Mayo Clinic researchers say. It is a common cause of disability: 1 of every 5 rheumatoid arthritis patients is unable to work two years after diagnosis, and within five years, that rises to one-third. Life expectancy drops by up to five years.

2 Jul 2012

Cerulean commences dosing in CRLX101-Avastin combination study for metastatic renal cell carcinoma

Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a Phase 1b/2a study of its lead product candidate, CRLX101, in combination with Avastin, in metastatic renal cell carcinoma (mRCC) patients. The company also announced the completion of enrollment of its randomized Phase 2 study in advanced non-small cell lung cancer.

2 Jul 2012

FDA approves Roche's new HIV viral load test

Roche announced today that a new HIV viral load test has been approved by the United States Food and Drug Administration (FDA) and will be commercially available in the US later this year.

2 Jul 2012

Abnormal bone marrow stem cells drive development of myelodysplastic syndromes

Researchers at Albert Einstein College of Medicine of Yeshiva University have found that abnormal bone marrow stem cells drive the development of myelodysplastic syndromes (MDS), serious blood diseases that are common among the elderly and that can progress to acute leukemia. The findings could lead to targeted therapies against MDS and prevent MDS-related cancers. The study is published today in the online edition of the journal Blood.

2 Jul 2012

Enrollment complete in Cerulean CRLX101 Phase 2 study for non-small cell lung cancer

Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that it has completed enrollment of a randomized Phase 2 study of its lead candidate, CRLX101, in advanced non-small cell lung cancer (NSCLC). The company also announced that it has dosed the first patient in a second tumor type.

2 Jul 2012

Rexahn submits RX-5902 IND to FDA for treatment of advanced or metastatic solid tumors

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted an investigational new drug application (IND) to the Food and Drug Administration for a first-in-human study of RX-5902 to treat advanced or metastatic solid tumors.

2 Jul 2012

Pediatric pain still common in hospitals

Despite advances in the understanding and treatment of pediatric pain, many hospitalized children continue to experience serious pain, according to a Johns Hopkins Children’s Center study published online ahead of print in the journal Pain Management Nursing.

2 Jul 2012

Sosei completes SO-1105 Phase I trial for oropharyngeal candidiasis in Japan

Sosei Group Corporation, the biopharmaceutical company, today announces that its wholly owned Japanese subsidiary, Sosei Co., Ltd., has successfully completed a Japanese Phase I trial for SO-1105 for the treatment of oropharyngeal candidiasis.

2 Jul 2012

Obesity during adulthood linked to sexual and physical abuse during childhood

Investigators from Boston University School of Medicine (BUSM) and Boston University's Slone Epidemiology Center report research findings that may shed light on influences on obesity during adulthood. Appearing in the journal Pediatrics, the study found an association of severity of sexual and physical abuse during childhood and adolescence with obesity during adulthood.

2 Jul 2012

CytRx granted European patent for tumor-targeting linker platform technology

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that the European Patent Office (EPO) has issued a patent covering the Company's tumor-targeting linker platform technology and pharmaceutical compositions.

2 Jul 2012

New treatment target against metastatic pancreatic cancer

Detailed analysis of genes expressed in circulating tumor cells (CTCs) -- cells that break off from solid tumors and travel through the bloodstream -- has identified a potential treatment target in metastatic pancreatic cancer.

2 Jul 2012

New platform for analysis of next generation sequencing data developed by Compugen

Compugen Ltd. (NASDAQ: CGEN) announced today the development of "NexGen," a new platform designed to significantly enhance Compugen’s overall infrastructure for predictive drug and drug target discovery. NexGen is designed to analyze Next Generation Sequencing data which is now beginning to be generated worldwide through RNA-Seq methodology.

2 Jul 2012

Blocking AXL protein may prevent resistance to lung cancer drug

People with lung cancer who are treated with the drug Tarceva face a daunting uncertainty: although their tumors may initially shrink, it's not a question of whether their cancer will return—it's a question of when. And for far too many, it happens far too soon.

2 Jul 2012

Study illuminates key step in the journey of inflammation-producing immune cells

Like detectives seeking footprints and other clues on a television "whodunit," science can also benefit from analyzing the tracks of important players in the body's molecular landscape. Klaus Ley, M.D., a scientist at the La Jolla Institute for Allergy & Immunology, has done just that and illuminated a key step in the journey of inflammation-producing immune cells.

2 Jul 2012

Cancer News and Research

Latest Cancer News and Research

Routine use of pelvic CT scans in Wilms tumor questioned

Procoagulant–fibrinolytic balance may predict hepatectomy thrombosis

Vitamin D–calcium combo reduces mortality in elderly

Study investigates association between SCC and cutaneous HPV types belonging to five different genera

Prostate Cancer Center of New Jersey earns ACR-ASTRO accreditation in radiation oncology

Onyx commences ENDEAVOR Kyprolis Phase 3 trial for relapsed multiple myeloma

Current diagnosis and treatment approaches for rheumatoid arthritis

Cerulean commences dosing in CRLX101-Avastin combination study for metastatic renal cell carcinoma

FDA approves Roche's new HIV viral load test

Abnormal bone marrow stem cells drive development of myelodysplastic syndromes

Enrollment complete in Cerulean CRLX101 Phase 2 study for non-small cell lung cancer

Rexahn submits RX-5902 IND to FDA for treatment of advanced or metastatic solid tumors

Pediatric pain still common in hospitals

Sosei completes SO-1105 Phase I trial for oropharyngeal candidiasis in Japan

Obesity during adulthood linked to sexual and physical abuse during childhood

CytRx granted European patent for tumor-targeting linker platform technology

New treatment target against metastatic pancreatic cancer

New platform for analysis of next generation sequencing data developed by Compugen

Blocking AXL protein may prevent resistance to lung cancer drug

Study illuminates key step in the journey of inflammation-producing immune cells

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in